Pharmacy Related Regulatory Changes in LTC. By: Anastasia Sidor, PharmD, BCGP Consultant Pharmacist Director Brockie Pharmatech
|
|
- Adela Phelps
- 5 years ago
- Views:
Transcription
1 Pharmacy Related Regulatory Changes in LTC By: Anastasia Sidor, PharmD, BCGP Consultant Pharmacist Director Brockie Pharmatech
2 Objectives 1. Contrast the difference between regulation and guidance within the State Operations Manual - Appendix PP Guidance to Surveyors 2. List the components of the unnecessary drug definition 3. Identify new psych regulations and changes to previous psych regulations
3 Application questions Use Socrative app or website Room: REGS
4 State Operations Manual
5 State Operations Manual Appendix PP Guidance to Surveyors for Long Term Care Facilities 749 pages Interpretation of regulations for the survey team Provides consistency in evaluating a nursing home s compliance with regulations Mega Rule Changes to the State Operations Manual Implemented in 3 phases Phase 1 Nov 28, 2016 Phase 2 Nov 28, 2017 Phase 3 Nov 28, 2019
6 Regulation vs. guidance All citations must be based on regulatory or statutory requirements May not be cited on interpretive guidelines Guidance to surveyors Must and shall indicative of requirements May and should suggest best practices, considered permissive standards Often the regulations are a few sentences, and guidance is paragraphs/pages long
7 Friendly advice Although citations are supposed to be based on regulation, not guidance, the surest way of avoiding citation is to follow the regulation and guidance as closely as possible Appeal any citations based on guidance rather than regulation Keep memo on hand during survey if you receive a citation based on guidance (link below) Certification/SurveyCertificationGenInfo/Downloads/SCLet ter08-10.pdf
8 F757 Unnecessary drug
9 Unnecessary drug Defined as a medication used in one or more of the following ways Excessive dose Guidance includes duplication of therapy Excessive duration Without appropriate monitoring Without appropriate indication for use Use in presence of adverse effects where dose should be reduced or discontinued
10 Question 1 Which of the following is NOT a component of the unnecessary drug definition? A) Excessive dose B) Use in absence of adverse effects C) Excessive duration D) Without appropriate monitoring
11 Unnecessary drug examples Citalopram 40mg qd in 88 yo w/ a. fib Excessive dose Amiodarone 400mg BID (has been on this dose for 2 months) Excessive duration, dose
12 Unnecessary drug examples Spironolactone 25mg qd with K=5.6mmol/L Presence of adverse effects Carvedilol 25mg qd with SBP consistently below <100 Presence of adverse effects
13 Question 2 Mrs. Jones is a 75 yo resident with HTN, a. fib, edema, and HLD. She takes metoprolol succinate 25mg qd, furosemide 20mg qd, digoxin 125mcg qd, and simvastatin 40mg qd. Routine lab monitoring includes BMP q 6 months, and lipid panel & LFTs annually. BP and HR are monitored and are WNL. Which medication could be considered an unnecessary drug according to the CMS definition? A) Metoprolol B) Furosemide C) Digoxin D) Simvastatin
14 F756 Drug regimen review (DRR)
15 Irregularity definition Definition of irregularity (c) Inconsistent with the standard of practice Not supported by evidence Inhibits intended outcomes from being achieved Untreated conditions that may require initiating medication Unnecessary drug Definition updated to include unnecessary drug
16 Irregularity examples Eliquis 5mg BID for a. fib in a 92 yo with a Scr=1.74mg/dL, weight=65kg (143 lbs) Inconsistent with standard of practice & not supported by evidence Donepezil 10mg for dementia and tolterodine 2mg BID for OAB Inhibits intended outcomes from being achieved
17 Irregularity examples 75 yo with a. fib not on anticoagulation with high risk for embolism Untreated conditions that may require drug initiation Amitriptyline 100mg qd for depression in a rehab resident experiencing sedation, confusion, blurry vision Inhibits intended outcomes from being achieved
18 Question 3 Mr. Jenkins is a 82 yo male with Parkinson s disease, Parkinson s psychosis, depression, and hypertension. His medication list consists of carbidopa/levodopa 25/100mg q 4 hours, olanzapine 5mg BID, sertraline 75mg qd, and metoprolol tartrate 50mg BID. Despite changes to Sinemet order, he persists with gait issues and falls. The consultant pharmacist is doing a monthly medication regimen review. Which medication order may be considered an irregularity and should be reported to the prescriber? A) Carbidopa/ levodopa B) Olanzapine C) Sertraline D) Metoprolol
19 Changes to the MRR process Monthly drug regimen review must include a review of the medical record (c)(2) Medical director provided with report of irregularities (c)(4) Attending physician must document response in medical record Action taken to address irregularity or Rationale provided if no changes made (c)(4) Pharmacist must report each irregularity and include resident name, drug, and specify irregularity (c)(4)
20 Changes to the MRR process Policy and procedure (P&P) must be in place for the MRR (c)(5) Regulation: Must include timeframes for steps in the process Must have P&P specific to what a pharmacist does when immediate attention is needed Guidance: Should address procedure for residents staying for 30 days or less Should address change in condition MRR
21 Changes to the MRR process Related regulation F (g)(14) Immediate notification required when treatment needs to be changed significantly Physician Resident Resident s representative (if applicable) Guidance: includes wording such as potential adverse consequence of a medication.
22 Question 4 You are writing a policy & procedure for the consultant pharmacist MRR. Identify the pieces that are not required by regulations, but suggested by guidance. A) Procedure for residents staying 30 days or less B) Procedure for what pharmacist does if immediate attention is needed C) Procedure for change in condition MRR D) Timeframes for each step in the process E) A & B F) A & C
23 F758 - Psychotropics
24 Psychotropic definition Definition psychotropic drug updated (c)(3) any drug that affects brain activities associated with mental processes and behavior. These drugs include, but are not limited to, (i) Anti-psychotic; (ii) Anti-depressant; (iii) Anti-anxiety; and (iv) Hypnotic.
25 Psychotropic drugs Guidance says Other medications which may affect brain activity such as central nervous system agents, mood stabilizers, anticonvulsants, muscle relaxants, anti-cholinergic medications, antihistamines, NMDA receptor modulators, and over the counter natural or herbal products must also only be given with a documented clinical indication consistent with accepted clinical standards of practice. Residents who take these medications must be monitored for any adverse consequences, specifically increased confusion or over-sedation.
26 Psychotropic drugs (e) Psychotropic Drugs. Based on a comprehensive assessment of a resident, the facility must ensure that (e)(1) Residents who have not used psychotropic drugs are not given these drugs unless the medication is necessary to treat a specific condition as diagnosed and documented in the clinical record; (e)(2) Residents who use psychotropic drugs receive gradual dose reductions, and behavioral interventions, unless clinically contraindicated, in an effort to discontinue these drugs
27 Gradual dose reduction (GDR) frequency Guidance: Twice within the first year (of admission or of starting medication) In 2 separate quarters Separated by at least 1 month Annually after first year General accepted practice for hypnotics is to have quarterly GDRs Noteworthy words Psychotropic medications classes of medication not specified Must mentioned in guidance
28 GDRs Guidance: However, some residents with specific, enduring, progressive, or terminal conditions such as chronic depression, Parkinson s disease psychosis, or recurrent seizures may need specific types of psychotropic medications or other medications which affect brain activity indefinitely.
29 GDRs Guidance: NOTE: A medication may have been required to treat a medical symptom, and as a result, the medical symptom is no longer present. In some cases, the clinical goal of the continued use of the medication is to stabilize the symptoms of the disorder so that the resident can function at the highest level possible Although the symptom may no longer be present, the disease process is still present. For example, diseases may include: Chronic psychiatric illness such as schizophrenia or schizoaffective disorder, bipolar disorder, depression, or post-traumatic stress disorder; Neurological illness such as Huntington s disease or Tourette s syndrome; and Psychosis and psychotic episodes.
30
31 What is clear about psychotropic regs Indication/appropriate diagnosis documented in clinical record Behavioral interventions necessary Prior to initiating psychotropics To facilitate discontinuation of psychotropics Document in clinical record
32 What is clear about psychotropic regs GDRs required There are no exemptions for end of life There are no exemptions for diagnoses GDRs must be attempted twice in the 1 st year of admission or initiation, in 2 separate quarters, then yearly Hypnotics are not specified as having to be done quarterly, but is still the accepted standard Classes required: antidepressants, anxiolytics, antipsychotics, hypnotics
33 ?? What is unclear about GDRs Do the drugs in the expanded definition of psychotropic drug (anticonvulsants, muscle relaxers, etc) need to have GDRs? According to regulation itself, GDRs could be expected for all psychotropic drugs which could include medications such as anticonvulsants, muscle relaxers, etc Guidance could imply for these other classes (anticonvulsants, muscle relaxants, etc) that requirements may only include Clinical indication documented Monitor for adverse effects
34 Question 5 True or False: According to current regulations, a resident under hospice care would be exempt from a GDR on their lorazepam 0.5mg qd order. A. True B. False Reference here
35 Question 6 True or False: According to current regulations, a resident taking olanzapine 10mg qd for Tourette s is no longer exempt from GDRs. A. True B. False Reference here
36 Clarify the confusion Often confusion between psychotropic/psychoactive versus antipsychotic when speaking with facility staff Psychotropic is not an interchangeable term with antipsychotic Psychotropic/psychoactive is a broad term that encompasses the following medication classes Psychotropic/ psychoactive drugs Antipsychotics Anxiolytics Antidepressants Hypnotics Other
37 PRN antipsychotics Psychotropic drugs Antipsychotics Anxiolytics Antidepressants Hypnotics Other
38 PRN antipsychotics PRN antipsychotic order (e)(5) Strict 14 day order limit Diagnosis specified & documented in clinical record May only be ordered again for another 14 day period if the PCP evaluates the resident in person (per guidance) to assess appropriateness of the medication and provides rationale Is the antipsychotic medication still needed on a PRN basis? What is the benefit of the medication to the resident? Have the resident s expressions/indications of distress improved as a result?
39 PRN antipsychotics Regulations do not mention exceptions for diagnoses or end of life situations Example: prochlorperazine PRN n/v is a first generation antipsychotic and would be subject to this 14 day rule Example: haloperidol PRN terminal restlessness also subject to 14 day rule
40 PRN psychotropics Psychotropic drugs Antipsychotics Anxiolytics Antidepressants Hypnotics Other
41 Other PRN psychotropics Other PRN psychotropics (anxiolytics, hypnotics, antidepressants) (e)(4) Diagnosis specified & documented Initial order only limited to 14 days To continue with PRN order, the prescriber must evaluate the resident, document rationale, and provide duration for PRN order In-person evaluation NOT required Duration should be a finite period of time indefinitely not appropriate
42 Question 7 Which order must be renewed/reviewed every 14 days? A. Lorazepam 0.5mg qd prn B. Quetiapine 25mg qd C. Haloperidol 1mg BID prn D. Zolpidem 5mg qhs prn
43 Question 8 In order for haloperidol 1mg BID prn to be renewed every 14 days, what must occur and be documented? A. Rationale provided B. Nursing supervisor evaluation of resident C. Diagnosis provided D. Physician evaluation of resident E. A & C F. A, B & C G. A, C & D Reference here
44 Friendly advice PRN psychoactive orders have been a major target this year Increases in frequency of PRN orders have been considered new orders and must have a 14 day stop date For example: lorazepam 0.5mg BID prn increased to lorazepam 0.5mg q8 hrs prn Considered a new order Should have had a 14 day stop date with rationale, duration, and indicated documented in clinical record
45 F881 Antibiotic stewardship
46 Antibiotic stewardship (ABS) (a) The facility must establish an infection prevention and control program (IPCP) that must include, at a minimum, the following elements: (a)(3) An antibiotic stewardship program that includes antibiotic use protocols and a system to monitor antibiotic use.
47 Antibiotic stewardship Guidance: protocols must: Play a role in overall infection prevention/control program Be reviewed at least yearly or as needed Establish a system to monitor and report antibiotic use and resistance patterns Establish frequency of monitoring/review of orders and how this feedback will be disseminated Utilize standardized tools and criteria Include mode of education on ABS to prescribers and staff
48 Antibiotic stewardship & the MRR Guidance: Licensed pharmacist must review antibiotic order during MRR Review may occur retrospectively Pharmacist communicate findings and must report any irregularities
49 Friendly advice Find ways to streamline your work work smarter, not harder or in this case, work smarter, not longer If you have multiple consultants, create uniformity throughout team Get the appropriate resources they are some antimicrobial apps for as low as $30/year that will simplify your reviews
50 F882 Infection Preventionist
51 Infection Preventionist Phase 3 implementation Nov 28, 2019 Part time position Professionally trained in nursing, medical technology, microbiology, epidemiology, or related profession and qualified by certification, experience, training or education Requires specialized training in infection prevention and control Must sit on QAA committee
52 Phase 2 CMS memo issued 11/24/17 Moratorium on certain Phase 2 requirements F758 Psychotropic medications related to PRN psych limitations F881 Antibiotic stewardship Other non-pharmacy related requirements included 18 month moratorium on financial penalties F-tags incurred from specified requirements will not be used to calculate Star Rating for 12 months Facilities required to follow Phase 2 requirements and may be cited on all F-tags Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and- Regions-Items/Survey-and-Cert-Letter html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending
53 F759 & F760 Medication errors
54 Medication errors Guidance: Crushing Oral Medications To address concerns with physical and chemical incompatibility and complete dosing, best practice would be to separately crush each medication and separately administer each medication with food. However, separating crushed medications may not be appropriate for all residents and is generally not counted as a medication error unless there are instructions not to crush the medication(s). Facilities should use a personcentered, individualized approach to administering all medications. If a surveyor identifies concerns related to crushing and combining oral medications, the surveyor should evaluate whether facility staff have worked with the resident/representative and appropriate clinicians (e.g., the consultant pharmacist, attending physician, medical director) to determine the most appropriate method for administering crushed medications which considers each resident s safety, needs, medication schedule, preferences, and functional ability.
55 Person-centered care F760 guidance: Resident has right to choose health care schedules Medication administration times must be considered Some medications have flexible administration times Some medications remain time-critical to achieve therapeutic effect
56 Odds & ends F (c)(2) - pre/post discharge medication reconciliation **Phase 3 F Each LTC facility, including a facility that is part of a multiunit chain, must develop, implement, and maintain an effective, comprehensive, data-driven QAPI program that focuses on indicators of the outcomes of care and quality of life F (d) guidance that recommends that PPSV23 & PVC13 be administered in appropriate time frames to all adults older than 65 per ACIP
57 F755 Pharmacy services
58 Liquid controlled medications Guidance: Liquid controlled medications are often dispensed in multi-dose containers which indicate approximate volume. The containers may also be opaque to protect the medication from light. It should be noted that absolute accuracy in tracking volume and use of liquid controlled medications may not be possible. The actual volume in these containers may be slightly over or under the manufacturer s stated volume depending on the shape and material of the container and the formulation of the medication such as thick liquid suspensions. The opaque container, measurement markings, manufacturer fill volume variation, and method for recording usage all make detection of diversion for liquid controlled medications more difficult. The general standard of practice for documenting usage of liquid controlled medications is to record the starting volume from the label, record each dose administered, subtract the dose administered from the previously recorded volume, and record the remaining amount. Any observed discrepancy between the recorded amount and what appears to be remaining in the container should be reported according to facility policy. Manufacturer s instructions may list the estimated volume variance (e.g., 30 ml plus or minus 2.5 ml). For liquid controlled medications, signs of diversion may include: an observable discrepancy between the written balances of remaining medication compared to the remaining amount in the bottle upon visual inspection; changes in the viscosity or color of the medication; reports of spills; and, as with other controlled medications, statements from a resident that the medication is not working.
59 Impact Act: Improving Medicare Post- Acute Care Transformation Act
60 Impact Act Passed in 2014 Implementation date of Oct 1, 2018 Goal is to standardize assessment data over post-acute care Not exclusive to SNFs (home health, rehab, SNFs, etc all included)
61 Impact Act Pharmacist is not specified to participate in the activities of the Impact Act Pharmacy-related components: Medication reconciliation (domain) DRR (measure) Definition inconsistent with DRR definition in State Operations Manual DRR focuses on identifying clinically significant medication issues Must be reported to physician and responded to before midnight of next day For SNFs, results and compliance must be reported in Minimum Data Set (MDS)
62 References 1) Centers for Medicare and Medicaid Services. (2008). Use of Interpretive Guidance by Surveyors for Long Term Care Facilities. Retrieved from: Certification/SurveyCertificationGenInfo/Downloads/SCLetter08-10.pdf 2) Centers for Medicare and Medicaid Services. (2017). State Operations Manual. Retrieved from: 3) American Geriatrics Society. (2015). American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Retrieved from: 4) Centers for Medicare and Medicaid Services. (2017). Temporary Enforcement Delays for Certain Phase 2 F- Tags and Changes to Nursing Home Compare. Retrieved from: Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions-Items/Surveyand-Cert-Letter html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending 5) Centers for Medicare and Medicaid Services. (2018). IMPACT Act of 2014 Data Standardization & Cross Setting Measures. Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-of-2014-Data-Standardization-and-Cross-Setting- Measures.html
63 Questions?
Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics. Session Objectives. January 2018
Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics Bridget McCrate Protus, PharmD, MLIS, BCGP, CDP Director of Drug Information Optum Hospice Pharmacy Services Session Objectives
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationIntegrating INTERACT into Interim Pharmacist Reviews
Integrating INTERACT into Interim Pharmacist Reviews Chad R. Worz, Pharm.D. President, Medication Managers, LLC Adjunct Assistant Professor of Pharmacy Practice, University of Cincinnati, College of Pharmacy
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More information12/17/2012. Unnecessary Drugs
Nursing Home Social Work Webinar Series December 19, 2012 Dr. Robin P. Bonifas, PhD, MSW Arizona State University School of Social Work Importance of familiarity with psychotropic medication regulations.
More informationThe Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State
The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,
More informationBehavioral Health Evaluation
This document is intended to serve as a template for a behavioral health committee meeting in an extended care facility. The State Operations Manual (SOM), Appendix PP - "Guidance to Surveyors for Long
More information9/11/2012. Clare I. Hays, MD, CMD
Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management
More informationOBJECTIVES. Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia
Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia Amy J. Osborn, NHA, PMP Executive Director, Health Services Advisory Group (HSAG) Rick Foley, PharmD,
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationAntibiotic Therapy: How long is long enough?
Antibiotic Therapy: How long is long enough? By: David Milstein, C.Ph., BS, MHSA CLINICAL & REGULATORY NEWS BY PHARMERICA Antibiotics are highly regarded as safe and effective, but as with all medications,
More informationUnderstanding Mental Health Preadmission Screening and Resident Review (PASRR) and Form Valerie Krueger Mental Health PASRR Specialist
Understanding Mental Health Preadmission Screening and Resident Review (PASRR) and Form 1012 Valerie Krueger Mental Health PASRR Specialist Session Objectives At the conclusion of this session participants
More informationAntidepressants for treatment of depression.
JR3 340 1 of 9 PSYCHOTROPIC MEDICATIONS PURPOSE The use of psychotropic medication as part of a youth's comprehensive mental health treatment plan may be beneficial. The administration of psychotropic
More informationVanderbilt & Qsource Webinar Series
Vanderbilt & Qsource Webinar Series Vanderbilt Medical Center Vanderbilt University Center for Quality Aging Qsource Session #1: Introduction to Dementia Care & QAPI Session #2: Dementia & Behavioral Disturbances
More informationTransitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018
Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Objectives Identify when to complete medication reconciliation Understand the importance
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationUpdates to CMS SOM rules on Psychosocial Issues, Deficiency Categorization, and Psychotropic Medication Use
Updates to CMS SOM rules on Psychosocial Issues, Deficiency Categorization, and Psychotropic Medication Use Stephen Eide R. Ph Oni Kinberg LCSW, MSSW Updates to the SOM On March 25, 2016 CMS sent out updates
More informationInnovative Opportunities for Pharmacists in the Evolving World of Healthcare
Innovative Opportunities for Pharmacists in the Evolving World of Healthcare Christina Pornprasert, PharmD Population Health Clinical Pharmacist Hartford Healthcare Integrated Care Partners Assistant Clinical
More informationObjectives. July
Comprehensive Review of Regulations & Interpretive Guidance for Top F-Tags Unnecessary Drugs F757-F758 Objectives 1. Identify the regulatory requirements related to Unnecessary Drugs 2. Identify survey
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationFull details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More information3/17/2017. Innovative Opportunities for Pharmacists in the Evolving World of Healthcare. Elderly represent about of our emergency medical services:
Innovative Opportunities for Pharmacists in the Evolving World of Healthcare Christina Pornprasert, PharmD Population Health Clinical Pharmacist Hartford Healthcare Integrated Care Partners Addolorata
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationAdult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160
Adult Mental Health Services Comparison Create and maintain a document in an easily accessible location on such health carrier's Internet web site that (i) (ii) compares each aspect of such clinical review
More informationPSYCHOTROPIC MEDICATIONS IN LTC CHALLENGES AND OPPORTUNITIES FOR BEST PRACTICES
PSYCHOTROPIC MEDICATIONS IN LTC CHALLENGES AND OPPORTUNITIES FOR BEST PRACTICES Coleen Kayden, RPh Medication Information Services Division of Williams Apothecary Conflicts of Interest None to report PANAC
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationBack to Basics: The Basics of Medication Monitoring
DIAMOND PHARMACY SERVICES Back to Basics: The Basics of Medication Monitoring Presented by: Dr. Deborah Milito, Pharm. D., CGP. Director of Clinical and Consultant Services Skilled Division Annual Educational
More information483.45(d) Unnecessary Drugs General. Each resident s drug regimen must be free from unnecessary drugs. An unnecessary drug is any drug when used
F757 483.45(d) Unnecessary Drugs General. Each resident s drug regimen must be free from unnecessary drugs. An unnecessary drug is any drug when used 483.45(d)(1) In excessive dose (including duplicate
More informationClinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.
Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationDuquesne University Mylan School of Pharmacy
Duquesne University Mylan School of Pharmacy Course Title: Pharmacy in Long Term Care Academic Semester: Fall 2016 Course Number: PHPR 466 Credits: 3 Prerequisites: None Course Hours: Tuesday 6-9 pm Please
More informationThe Pediatric Behavioral Health Medication Initiative September 2016
The Pediatric Behavioral Health Medication Initiative Neha Kashalikar, PharmD Clinical Consultant Pharmacist UMass Medical School Clinical Pharmacy Services Background Several studies investigated trends
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationNon- Pharmacologic Behavioral Interventions
CLINICAL & REGULATORY NEWS BY PHARMERICA JAN/FEB 2018 Non- Pharmacologic Behavioral Interventions By: Jim Mooney, RPh Impairments in abilities such as memory, language, reasoning and judgement affect an
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationNational Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS
National Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS Key Points for RWE in Randomized Clinical Trials What is the
More informationAntipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
More informationNew England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm. Presenters.
New England QIN-QIO Reducing Unnecessary Antipsychotic Medications Affinity Group Call Thursday, January 19 th 3-4:00 pm Call-In Information: 1-888-895-6448 Code: 7362894 Log-In Information: https://qualidigm.adobeconnect.com/affinity/
More informationPromoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationFall Prevention in Hospice (A pharmacologic and nonpharmacologic approach)
Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Chinenye Emereole, Pharm.D. Clinical Pharmacist Hospice Pharmacy Solutions Objectives Assess and identify hospice patients who
More informationEffects of Home Antipsychotic Reinitiation in ICU Patients with a History of Mental Illness
Effects of Home Antipsychotic Reinitiation in ICU Patients with a History of Mental Illness Gary Sweet, PharmD PGY-1 Pharmacy Practice Resident St. John Medical Center, Tulsa, OK Conflict of Interest Nothing
More informationPain Management and Opioid Use in the Elderly
Pain Management and Opioid Use in the Elderly By Jim Mooney, RPh CLINICAL & REGULATORY NEWS BY PHARMERICA JULY/AUG 2018 Pain is common in older adults and is associated with the increased prevalence of
More informationAntipsychotic use in Dementia care. Jabbar Fazeli, MD
Antipsychotic use in Dementia care Jabbar Fazeli, MD www.mainegeriatrics.com What changed in 2012? NY times- May 9, 2011!! Antipsychotic Drugs Called Hazardous for the Elderly - referencing the OIG audit
More informationReduction of High Risk Medications Using A Quality Initiative Perspective
Reduction of High Risk Medications Using A Quality Initiative Perspective Richard Mueller PharmD, MBA, MS, Director of Pharmacy Dianne Hempel BSN, RN Quality Improvement Coordinator Objectives Learn what
More informationUnnecessary Medications Sampling Algorithm for QIS
Overview ASE-Q selects five Census Sample residents for the Unnecessary Medications sample. The sampling algorithm is based on surveyor responses to selected questions in the Census Sample resident observation,
More informationGuidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act
Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when
More information3/27/2013. Objectives. Psychopharmacology at the End of Life Nicole Thurston, MD
Psychopharmacology at the End of Life Nicole Thurston, MD Psychiatrist Mountain States Tumor Institute Objectives Describe 2 common psychiatric symptoms that can present at or near end of life. Review
More informationIntroducing ValueOptions Clinical Care Alerts
Introducing ValueOptions Clinical Care Alerts January 2013 Agenda What are Clinical Care Alerts? How does it work? What are the benefits? Questions and Answers 2 The Issue of Poor Medication Adherence
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationThe Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability
The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability Danielle Adams Principal Clinical Pharmacist Pharmacy and Medicines Optimisation Team HPFT July 2017 1
More informationClinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
More informationSCCMHD: Quality Improvement Medication Monitoring Chart Review Summary Report Fiscal Year: , January to March
BACKGROUND Chart review is an integral part of Mental Health Department Quality Improvement Program and mandated for clients who are Medi-Cal beneficiaries. Quality Improvement Medication Monitoring Program
More informationDepression: Assessment and Treatment For Older Adults
Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this
More informationPOLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE
POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE Jeannie Kim Lee, PharmD, BCPS, CGP Clinical Pharmacy Director College of Pharmacy The University of Arizona Learning Objectives: State the risks of
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationMeds and Falls: Keep in Step with your Meds
Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu
More informationPRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist
PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines
More informationPsychotropic Medication
FOM 802-1 1 of 10 OVERVIEW The use of psychotropic medication as part of a child s comprehensive mental health treatment plan may be beneficial and should include consideration of all alternative interventions.
More informationScreening Summary (SS2)
15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social
More informationStrategies for Successful Operationalizing Infection Prevention and Control for Today s Long-Term Care Facilities
Strategies for Successful Operationalizing Infection Prevention and Control for Today s Long-Term Care Facilities SUSAN LAGRANGE, RN, BSN, NHA, CDONA, FACDONA, CIMT DIRECTOR OF EDUCATION PATHWAY HEALTH
More informationFrom the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care
May 2015 Issue From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care Behavior Monitoring When is behavior monitoring required? In Long-term care, medications are
More informationPSYCHOTROPIC SOLUTIONS
PSYCHOTROPIC SOLUTIONS A proactive approach to antipsychotic medication management A Quality Use of Medicines initiative by Choice Aged Care Copyright 2018 Key Senate Committee Recommendations: All RACF
More informationClinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.
Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder
More informationLong Term Services Division. Supersedes: Policy Governing Behavior Support Service Planning, 1/19/96 and LTSD Behavior Support Policy Revision 6/23/00
Department of Health Long Term Services Division POLICY Policy Title: Psychotropic Medication Use Policy Number: Supersedes: Policy Governing Behavior Support Service Planning, 1/19/96 and LTSD Behavior
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationNavigating the Road to Efficient Medication Use
Navigating the Road to Efficient Medication Use Molly R. Sinert, RPh, PharmD Clinical Pharmacist HospiScript Services LLC a Catamaran Rx Company October 28, 2013 Objectives Describe the components of the
More informationTitle: Antipsychotic Use in Persons with Dementia CMS ID: ARCO3 NQF #: N/A
Source(s) Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p. Measure Domain Clinical Quality Measures:
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationBock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201
Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201 State Project Director- Bliss Beeman, RN Clinical Associate- Shelley Smith, RN Administrative Assistant- Viki DeClerk bockarkansas@gmail.com
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationADMINISTRATIVE POLICY AND PROCEDURE
Page 1 of 6 SECTION: Medical SUBJECT: Electroconvulsive Therapy (ECT) DATE OF ORIGIN: 10/1/96 REVIEW DATES: 7/1/98, 10/1/99, 7/1/02, 7/1/04, 10/1/05, 5/1/09, 1/3/13, 7/1/15, 8/1/16 EFFECTIVE DATE: 3/24/17
More informationProviderNews FEBRUARY
ProviderNews FEBRUARY 2017 Reminder: decimal billing required on time-based therapy codes for BadgerCare Plus members In accordance with Forward Health guidelines, Security Health Plan requires decimal
More informationENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS
ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS Philip J. Schneider, MS, FASHP The University of Arizona College of Pharmacy Learning Objectives: Describe the medication-use system and all interdependent
More informationHospital Transition Management. Barbara Wood, BSN, MBA
Hospital Transition Management Barbara Wood, BSN, MBA Director, Embedded Care Management Programs OBJECTIVES Improve health care quality for our patients by streamlining care transitions Reduce avoidable
More informationPolypharmacy 101. Acknowledgements. Disclosure. with special thanks to Jen Lehman, PharmD candidate
Polypharmacy 101 Kimberly Brand, PharmD Acknowledgements Original presentation by Chris Cawood, PharmD, with special thanks to Jen Lehman, PharmD candidate Content Contributions: Stephanie Powell, PharmD
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationUpdates and Clarifications to the Hospice Policy Chapter of the Benefit Policy Manual. Compliance for Hospice Providers Revised September 2014
Compliance Update National Hospice and Palliative Care Organization Regulatory & Compliance www.nhpco.org/regulatory Updates and Clarifications to the Hospice Policy Chapter of the Benefit Policy Manual
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationSiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]
SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationA Systematic Approach to
A Systematic Approach to Drug Regimen Review REVISITING INTRODUCTION This article is the third in a threepart series exploring drug regimen review (DRR) over the last 30 years. In the first part, we explored
More informationMedicine Related Falls Risk Assessment Tool (MRFRAT)
Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine
More informationQM Reports Technical Specifications: Version 1.0
Exhibit 271 Introduction The measures contained on the Quality Measure (QM) Reports are calculated in two major steps. In the first step, two samples of assessments are selected: a long-stay sample and
More informationKEY BEHAVIORAL MEASURES
2019 HEDIS AT-A-GLANCE: KEY BEHAVIORAL MEASURES (18 Years and Older) At WellCare, we value everything you do to deliver quality care for our members your patients to make sure they have a positive healthcare
More informationLEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018
LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018 DISCLAIMER The material presented is general legal information and is not legal advice. Specific
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCurbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care
Curbing the High Rates of Psychotropic Medication Prescriptions among Children and Youth in Foster Care Appendices Appendix A Psych Meds Data Indicators by State The data elements being collected by the
More informationPreventing Falls in Older Adults A Matter of Safety
Preventing Falls in Older Adults A Matter of Safety Roger Tam, BSc. Pharm. Wal-Mart Clinical Designated Pharmacist Falls Prevention Pharmacist Specialist NCCHC-Pre/Post Test Educator Q.U.I.T Educator Overview
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationMedicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At-Risk Population (HTN-2): Measure 28 Hypertension (HTN): Controlling High Blood Pressure ACO_QRM28PPTv9_0518_IA
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationProposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)
Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health
More information